Lead Opinion
{ 1 The United States Court of Appeals for the Tenth Circuit (Tenth Circuit) certified a single question of first impression to this Court under the Revised Uniform Certifica-
"Whether 21 U.S.C. 3872 of the Federal Food, Drug, and Cosmetic Act (FDCA), 21 U.S.C. § 301 et seq., providing that all violations of the Act shall be prosecuted in the name of the United States, prohibits Oklahoma from recognizing a claim for negligence per se3 based on violation of a federal regulation under the Medical Device Amendments (MDA) to the FDCA?"4
The question is answered in the negative.
CERTIFIED FACTS
12 The plaintiff/appellant, Brian C. Howard, M.D. (Howard/patient), received a knee replacement manufactured by the defendant, Sulzer Orthopedics, Inc. (Sul-zer/manufacturer).
13 The long and tortured litigation trail began in this case in 2002 in the Northern District of Oklahoma. However, because the Howards' complaint was one of many concerning Sulzer implants, the Judicial Panel on Multi-District Litigation consolidated the eases in the Northern District of Ohio. Sulzer entered into a settlement agreement with patients receiving implants the manufacturer identified as having undergone a cleaning process which left lubricating machine oil on the implants. However, Howard's case was excluded from the settlement because his device was not in the lot Sulzer identified as being cleaned inappropriately.
4 Initially, the Ohio district court refused to dismiss Howard's negligence per se claim. Thereafter, Sulzer filed a summary judgment motion alleging that the negligence claim was preempted based on the implant's Pre-Mar-ket Approval (PMA) application. A PMA prescribes the manufacturer's obligations in manufacturing and distributing the device. Sulzer contended that Howard's device met all the prescribed standards. Nevertheless, Howard argued that the PMA also required Sulzer to follow the more general Good Manufacturing Practices (GMPs) incorporated in the PMA. GMPs are FDCA regulations based upon manufacturing standards that apply to all FDCA-regulated medical devices.
15 The Howards appealed the dismissal of their negligence per se claim to the Sixth Cireuit They argued that 21 CER. § 820.70(b),
T6 On remand, the cause was transferred back to the Northern District of Oklahoma where Sulzer renewed its motion for summary judgment. The manufacturer argued that the non-preempted claim for negligence per se was not cognizable under Oklahoma state law. The district court agreed, dismissing the cause.
17 The Howards appealed to the United States Court of Appeals for the Tenth Circuit (Tenth Cireuit). The Tenth Circuit certified a single question of first impression to this Court on July 9, 2012 pursuant to the Revised Uniform Certification of Questions of Law Act, 20 O.S8.2011 §§ 1601, et seq. We set a briefing cycle which was concluded with the filing of the patient's response brief on August 3, 2012.
REGULATORY BACKGROUND
18 The Federal Food, Drug, and Cosmetic Act (FDCA), 21 U.S.C. § 801 et seq., requires
T 9 Class III devices must complete a thorough review process before they may be marketed. Pre-Market Approval (PMA) applications must be submitted and approved before medical devices may be distributed. A PMA prescribes the manufacturer's obligations in manufacturing and distributing the device. It is focused on safety, requiring that a device be made with almost no deviations from the specifications in its approval application.
1 10 Oklahoma law allows private individuals to maintain a parallel claim for negligence per se based on violation of a federal regulation whose enforcement lies with a governmental entity.
11 a) Federal regulations may form the basis of a negligence per se claim under Oklahoma law.
112 Howard asserts that Oklahoma law will allow a claim for negligence per se to proceed based on the violation of a federal regulation. The patient contends that such a position is supported by a recent opinion promulgated by this Court. Sulzer argues that federal regulations are not the type of law which should give rise to negligence per se claims. The manufacturer also insists that recognizing such a claim would contravene legislative intent where no clear standard of conduct is outlined. We are not persuaded by Sulzer's arguments.
118 The negligence per se doctrine is employed to substitute statutory standards for parallel common law, reasonable care duties. When courts adopt statutory standards for causes of action for negligence, the statute's violation constitutes negligence per se.
14 Approximately six months before the instant question was certified to this Court, we issued an opinion in Covel v. Rodriguez,
... [I)n addition to the duty to exercise ordinary care there are also duties imposed by statute, and that if they found that a person violated any one of the following statutes or federal regulations, and that the violation was the direct cause of the injury, then such violation in and of itself would make such person negligent. ... [Bold added. Italies in original.]
The instruction given in the cause contained references to federal motor carrier safety regulations. In Covel, we determined that there was no prejudicial misstatement of law and no fundamental error in the instructions given on negligence per se. Such a position was adopted as early as 1984 in Woodis v. OG & E Co.,
1 15 We have long recognized that validly promulgated and executed regulations have the full force and effect of law
16 The Court of Civil Appeals has held in three cases that federal regulations would not support a claim for negligence per se. In Claborn v. Plains Cotton Cooperative Ass'n,
17 Claborn, Rosson, and Christian do not bear the imprimatur of this Court. At best, they are of only persuasive value.
119 Sulzer argues that because the FDCA regulations relating to medical devices do not contain a provision allowing private individuals to bring tort claims for their enforcement, they cannot support a negligence per se claim. The manufacturer insists that recognizing such a claim would be contrary to expressed legislative intent providing that "all such proceedings for the enforcement, or to restrain violations ... shall be by and in the name of the United States." [Emphasis supplied.]
120 We refused to recognize a private right of action for the prosecution of a consumer protection claim in Holbert v. Echeverria,
{ 21 We took a second look at the Consumer Protection Act in Walls v. American Tobacco Co.,
[Even where some statutory language seems to grant a private right of action, if the same or a related statute also clearly places enforcement in the hands of governmental authorities the right of action is exclusively vested in such governmental authority, [Emphasis provided.]
T 23 The cases discussed herein are not the only causes in which we have determined that where a statute expressly places the right of prosecution in a public entity, there can be no intent to create a private right of action.
1 24 The language of 21 U.S.C. § 887 provides that all actions to enforce violations of the FDCA "shall be by and in the name of the United States." There is little question that, under this Court's jurisprudence, Howard would have no authority to bring an enforcement action based on the violation of a federal regulation promulgated under the FDCA. Nevertheless, while Howard seeks to show violation of 21 C.EF.R. § 820.70(h),
125 The United States Supreme Court determined in Riegel v. Medtronic, Inc.,
T 26 The situation described in Medtronic as a "parallel claim" which should be allowed to proceed is precisely the situation presented here.
127 The United States Court of Appeals for the Sixth Cireuit (Sixth Cireuit) would have allowed the patient's suit to proceed. In an unpublished opinion, it held that Howard's negligence per se claim was not preempted by the amendments to the FDCA.
1 28 The Seventh Cireuit Court of Appeals held that, to the degree tort claims could be construed to allege that a defendant failed to meet the standards set forth in the government's approval process, the claims were not pre-empted. It reasoned that a state judgment premised on the truth of the allegations, set up no requirement different from or in addition to those established by the FDCA.
129 Although the federal court found a lack of evidence to support a prima facie case for the patients' claims in Valente v. Sofamor, SNC,
130 There is no unanimity in the courts which have addressed the issue of whether negligence per se claims should be allowed to proceed under the FDCA. This is demonstrated by the federal district court's ruling herein in which the Northern District determined that we would not acknowledge Howard's negligence per se claim because he was not a member of the class intended to be protected by the federal regulations.
181 We align ourselves with those jurisdictions which would allow a negligence
RESPONSE TO DISSENT
382 The dissent begins by doing what it criticizes the majority for having done: crafting the question certified to answer the issues it perceives will reach the result it prefers.
133 More exploration is required of the dissent's insistence that the purpose of the federal regulation at issue here is merely a "record keeping" function and asserts that the regulation is too "vague" to serve as a basis for a negligence per se claim. When faced with arguments similar to those championed by the dissent as to the purpose of the Medical Devices Act, the Seventh Circuit Court of Appeals relied on the Sixth Circuit's rejection of such an argument in this very case.
Like the Sixth Circuit in Howard, we do not see a sound legal basis for defendants' proposal to distinguish between general requirements and "concrete, device-specific" requirements.... [Fljlederal law is clear: for manufacturers of Class III medical devices, the Quality System Regulations and Current Good Manufacturing Practices adopted by the FDA under its delegated regulatory authority are legally binding requirements "The failure to comply with any applicable provision in this part [of the regulations] renders a device adulterated under section 501(h) of the act. Such a device, as well as any person responsible for the failure to comply, is subject to regulatory action...." [Emphasis supplied.]
Defendants' proposed distinction between concrete, product-specific requirements and more general requirements would also leave injured patients without any remedy for a wide range of harmful violations of federal law. The FDA regulations contain many requirements that are not concrete or product-specific, yet which are obviously vital to producing safe and effective medical devices. For example, the regulations require each manufacturer to "establish and maintain procedures to prevent contamination of equipment or product by substances that could reasonably be expected to have an adverse effect on product quality," 21 C.F.R. § 820.70(e), and to "establish and maintain procedures for the use and removal" of manufacturing material (such as lubricants or abrasives, or cleaning and disinfectant agents) "to ensure that it is removed or limited to an amount that does not adversely affect the device's quality." 21 C.F.R. § 820.70(b). If a patient were harmed by an implanted hip replacement system that was contaminated, for example, by a production worker's blood or mucus or by a Iubri-cant or abrasive that caused an infectionafter implantation, that contamination would present a substantial claim for violating requirements that are not "concrete" and "product-specific," yet which surely are essential for the manufacture of safe and effective medical devices for implantation in the human body. [Emphasis provided.]
{34 Most concerning is that the dissent seeks to be the "fact finder," a function which lies at the trial level and not with this Court. It would determine that Howard's reliance on the federal regulation is too tenuous to convince a reasonable person that the manufacturer's failure to properly follow the federal regulation at issue caused his injury. This is not the role of an appellate court. Even recognizing that there is a possibility that a jury deciding the common law claim might apply requirements more stringently than the FDA intended, the Seventh Cireuit refused to engage in a question that it found to present a "slippery slope" of whether a distinction could be drawn under the federal regulation between "concrete" and "product-specific requirements." Instead, it left those fact issues where we have done, in the realm of the fact-finder who will determine whether there was a violation which would support an award, something upon which we expressly refuse to comment or speculate.
CONCLUSION
135 Our determination that Howard should be allowed to utilize a negligence per se claim based upon violation of the federal regulation does not guarantee recovery of damages. Instead, we emphasize that negligence per se does not equate to lability per se. Simply because the law may presume negligence from a person's violation of the federal regulation does not mean that the law presumes that such negligence was the proximate cause of the harm inflicted.
CERTIFIED QUESTION ANSWERED.
Notes
. As originally certified, the question provides:
"Does Oklahoma recognize a claim for negligence per se based on an alleged violation of 21 C.F.R. § 820.70(b), a federal regulation promulgated pursuant to the Medical Device Amendments to the Food, Drug, and Cosmetic Act, even though those enactments do not allow private rights of action?"
Certification of Question of State Law, filed on July 9, 2012, providing in pertinent part at p. 7: "... [Wle conclude that the law of the case prevents us from reconsidering the implied-preemption question.... Having resolved that preemption analysis no longer has any place in this case, we turn to Oklahoma state law. ..."
Even if the preemption issue were before us, we likely would have taken the same position as that of Sixth Circuit, i.e. the Howards' claim would be allowed to go forward. The negligence per se claim is based on allegations that Sulzer did not clean the implant in accordance with the federal regulatory requirements. The United States Supreme Court has made it clear that state requirements are pre-empted only to the extent that they are different from, or in addition to the requirements imposed by federal law. States are not prevented from providing a damages remedy for claims premised on a violation of federal regulations. Riegel v. Medtronic, Inc., see note 10, infra; Medtronic v. Lohr, see note 10, infra.
. Title 21 U.S.C. § 337 providing in pertinent part:
"(a) Except as provided in subsection (b) of this section, all such proceedings for the enforcement, or to restrain violations, of this chapter shall be by and in the name of the United States...."
Subsection (b) allows states to bring actions in their own names for civil enforcement of the statute in certain instances.
. The negligence per se doctrine is employed to substitute statutory standards for parallel common law, reasonable care duties. When courts adopt statutory standards for causes of action for negligence, the statute's violation constitutes negligence per se. Busby v. Quail Creek Golf & Country Club,
. The federal regulation at issue is 21 CFR. § 820.70(h) providing:
"Manufacturing material. Where a manufacturing material could reasonably be expected to have an adverse effect on product quality, the manufacturer shall establish and maintain procedures for the use and removal of such manufacturing material to ensure that it is removed or limited to an amount that does not adversely affect the device's quality. The removal or reduction of such manufacturing material shall be documented."
. In answering a certified question, the Court does not presume facts outside those offered by the certification order. In re Harris,
. We refer to "Sulzer" as the manufacturer, as did the federal court, because that name had been utilized throughout the litigation. The parties are aware that Zimmer, Inc., is the proper defendant/appellee in the cause. Certification of Question of Law, filed with this Court on July 9, 2012.
. See generally, 21 CFR. § 820.
. 21 C.F.R. § 820.70(h), see note 4, supra.
. Howard v. Sulzer Orthopedics, Inc.,
. Riegel v. Medtronic, Inc.,
. Buckman Co. v. Plaintiffs' Legal Committee,
. Riegel v. Medtronic, Inc., see note 10, supra.
. Howard v. Sulzer Orthopedics, Inc., see note 9, infra.
. Title 21 C.F.R. § 820.70(h), see note 4, supra.
. Busby v. Quail Creek Golf & Country Club, 1994 OK. 63, ¶ 6,
. Lockhart v. Loosen,
. In re: Orthopedic Bone Screw Products Liability Litigation, see note 36, infra; In re TMI,
. Jones v. Oklahoma Natural Gas Co.,
. Hoar v. Aetna Casualty & Surety Co.,
. McClure v. ConocoPhillips Co.,
. Johnson v. Hillcrest Health Center, Inc.,
. Opinions released for publication by order of the Court of Civil Appeals are persuasive only and lack precedential effect. Rule 1.200, Supreme Court Rules, 12 O.$.2011, Ch. 5, App. 1; 20 0.S.2011 §§ 30.5 and 30.14.
. Title 21 U.S.C. § 337, see note 2, supra.
. It is correct that the word "shall" is ordinarily interpreted as implying a command or mandate and that "may" generally denotes permissive or discretional authority, we have held that a directory rather than mandatory construction may be given to the work "shall" upon a finding of strongly persuasive contrary legislative intent. State ex rel. Oklahoma Bar Ass'n. v. Mothershed,
. We note that in Walls v. American Tobacco Co.,
. Title 15 O.S. Supp.1988 § 761.1(A) providing in pertinent part:
''The commission of any act or practice declared to be a violation of the Consumer Protection Act shall render the violator Hable to the aggrieved consumer for the payment of actual damages sustained by the consumer and costs of litigation including reasonable attorney's fees, and the aggrieved consumer shall have a private right of action for damages ..."
. Title 15 0.S. Supp.1994 § 761.1(C) providing:
"Any person who is found to be in violation of the Oklahoma Consumer Protection Act in a civil action or who willfully violates the terms of any injunction or court order issued pursuant to the Consumer Protection Act shall forfeit and pay a civil penalty of not more than Ten ThousandDollars ($10,000.00) per violation, in addition to other penalties that may be imposed by the court, as the court shall deem necessary and proper. For the purposes of this section, the district court issuing an injunction shall retain jurisdiction, and in such cases, the Attorney General, acting in the name of the state, or a district attorney may petition for recovery of civil penalties."
. See, Walker v. Chouteau Lime Co., Inc.,
. 21 C.F.R. § 820.70(h), see note 4, supra.
. See, Medtronic, Inc. v. Lohr, see note 10, supra, providing that nothing denies states the right to provide a traditional damages remedy for violations of common-law duties when those duties parallel federal requirements. In Bates v. Dow Agrosciences LLC,
. Title 21 C.F.R. § 820.70(h), see note 4, supra.
. Howard v. Sulzer Orthopedics, Inc., see note 9, supra.
. Mitchell v. Collagen Corp.,
. Howard v. Sulzer Orthopedics, Inc.,
. Stengel v. Medtronic, Inc.,
. In re: Medtronic, Inc., Sprint Fidelis Leads Products Liability Litigation,
. Allen v. Delchamps, Inc.,
. This Court has adopted a three-part test for determining whether a private right of action may be implied from a regulatory statute. Pursuant to our opinion in Holbert v. Echeverria,
. See, 125, supra.
. See, 129, supra.
. Bausch v. Stryker Corp.,
"... The Sixth Circuit has rejected this approach. See Howard,382 Fed.Appx. at 440 (reversing summary judgment on preemption grounds, concluding that the Current Good Manufacturing Practices are 'not so vague as to be incapable of enforcement.)... ."
. Graham v. American Cyanamid Co.,
. Ohio Casualty Ins. Co. v. Todd,
Dissenting Opinion
with whom WINCHESTER, J. joins, dissenting.
11 The Tenth Circuit certified the following question to this Court:
Does Oklahoma recognize a claim for negli-genee per se based on an alleged violation of 21 C.EF.R. § 820.70(h), a federal regulation promulgated pursuant to the Medical Device Amendments to the Food, Drug, and Cosmetic Act, even though those enactments do not allow private rights of action?
In explaining its reasons for certifying this question, the Tenth Circuit pointed to three areas where Oklahoma law appears to be ambiguous: 1) Does Oklahoma law allow a claim for negligence per se based on an alleged violation of a federal regulation rather than a statute? 2) Does Oklahoma law bar a claim for negligence per se when the statute in question lacks a private right of action? and 38) Is 21 C.E.R. § 820.70(h) too ambiguous, under Oklahoma law, to support a claim for negligence per se? See Certification of Question of State Law, at 7-9 (July 8, 2012).
T2 My interpretation of the certified question and my understanding of the issues presented by the Tenth Circuit leads me to the conclusion that Oklahoma law does not recognize a claim for negligence per se based on an alleged violation of 21 C.F.R. § 820.70(h) regardless of whether the Medical Device Amendments to the Food, Drug, and Cos
3 The Defendant correctly points out that this Court has never allowed a negligence per se claim to go forward solely on an alleged violation of a federal regulation
T4 I cannot join today's opinion because the holding is too broad. In my view, any expansion of the law in this area should be done narrowly and on a case-by-case basis and only when the Plaintiff can prove that he or she is within the class meant to be protected by the regulation and that his or her injury was meant to be prevented by the regulation. The facts of today's case certainly do not warrant an expansion of our negli-genee per se law. First, for a negligence per se instruction to be proper under Oklahoma law, the terms of a statute must impose objective standards. See Athey,
15 Additionally, without any citation to authority or to the record, the Plaintiff asserts that "[the purpose of this requirement was to protect individuals who receive Sul-zer's implants and was designed to prevent the very risks that occurred in this case-damage caused to Dr. Howard because of Sulzer's failure to remove such substances."
. I see no reason to rely on cases such as Riegel v. Medtronic, Inc.,
. The Court of Civil Appeals in two different cases implied that a federal regulation could provide the basis for a negligence per se claim. However, in both of those cases, the COCA found that the Plaintiffs did not fall within the class of persons meant to be protected by the regulations. As such, the negligence per se theories could not go forward. See Claborn v. Plains Cotton Co-op. Ass'n,
. See, eg., Cornwell v. Union Pacific R.R.,
. 49 C.F.R. §§ 383.1; 383.113; 391.11; 391.31; 392.7.
. 47 0.8. §§ 11-311; 11-801(B)(2); 47 0.$.2004 § 6-101. In Covel, in evaluating the jury instructions as a whole to determine whether there was reversible error, this Court held that there was no prejudicial misstatement of the law and no fundamental error in the instructions given on negligence per se.
. See also Myers v. Mo. Pacific R.R. Co.,
. Howard v. Sulzer Orthopedics, Inc.,
. Brief in Chief of Appellants Brian C. Howard, M.D., and Suzanne Howard, at 11.
. Food and Drug Admin., OMB No. 0910-0073, Supporting Statement for Medical Devices: Current Good Manufacturing Practice (CGMP), Quality System (Q/S) Regulation, at 1, (updated as of Apr. 27, 2007) (emphasis added) http:/ www.fda.gov/OHRMS/DOCKETS/98fr/04n-0034-ss0000 1 .pdf.
The description of information collection requirements for 21 C.F.R. § 820.70(h) is listed as follows:
"21 CFR 820.70(h)-Recordkeeping
Manufacturers shall establish and maintain procedures for using and removing adverse manufacturing materials."
Id.
. The Plaintiff has pointed to nothing in his four appendices that would indicate that this GMP was meant to protect a certain class of individuals or a certain type of injury.
